Allogeneic HCT for sickle cell disease (SCD) can lead to survival rates exceeding 90%, according to results of a single-center study of 50 children with severe SCD. Median age at HCT was 8.3 years, and stem cell sources were bone marrow (n=39), cord blood (n=3), bone marrow and cord blood (n=7) and peripheral blood stem cells (n=1). All patients had one or more severe manifestations of SCD, including recurrent vaso-occlusive crises/acute chest syndrome (n=37), cerebral vasculopathy (n=27), and nephropathy (n=1). At a median follow up of 7.7 years, eight-year survival and event-free survival was 94.1% and 85.6%, respectively.
Dedeken L, et al. Br J Haematol
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Longer-Term HCT Outcomes for Severe Sickle Cell Disease in Childhood
Feb 2014